# Instituto Nacional de Cancerología

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/instituto-nacional-de-cancerologia/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 44.5 |
| Citations | 147,300 |
| City | Bogotá |
| Country | CO |
| Description | Instituto Nacional de Cancerología is a research organisation in Bogotá, CO. OpenAlex records 2,883 works and 147,300 citations for it. 1,597 researchers list it as their most recent affiliation. |
| Homepage | https://www.cancer.gov.co |
| OpenAlex ID | https://openalex.org/I4210119015 |
| Researchers | 1,597 |
| ROR ID | https://ror.org/02hdnbe80 |
| Type | healthcare |
| Works | 2,883 |

## University papers

Showing 12 of 15.

- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-for-second-line/)
- [Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-previously-treated-patients-with-advanced-non/)
- [Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/five-year-outcomes-from-the-randomized-phase-iii-trials-checkmate-017-and-057/)
- [A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors](https://scholariq.org/papers/a-phase-ii-study-of-epigenetic-therapy-with-hydralazine-and-magnesium-valproate/)
- [Epigenetics of cervical cancer. An overview and therapeutic perspectives](https://scholariq.org/papers/epigenetics-of-cervical-cancer-an-overview-and-therapeutic-perspectives/)
- [A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes](https://scholariq.org/papers/a-phase-i-study-of-hydralazine-to-demethylate-and-reactivate-the-expression-of/)
- [A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results](https://scholariq.org/papers/a-double-blind-placebo-controlled-randomized-phase-iii-trial-of-chemotherapy/)
- [Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study](https://scholariq.org/papers/histone-acetylation-and-histone-deacetylase-activity-of-magnesium-valproate-in/)
- [Nutritional Assessment Tools for the Identification of Malnutrition and Nutritional Risk Associated with Cancer Treatment](https://scholariq.org/papers/nutritional-assessment-tools-for-the-identification-of-malnutrition-and/)
- [Radiosensitizers in cervical cancer. Cisplatin and beyond](https://scholariq.org/papers/radiosensitizers-in-cervical-cancer-cisplatin-and-beyond/)
- [A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation](https://scholariq.org/papers/a-phase-ii-study-of-multimodality-treatment-for-locally-advanced-cervical-cancer/)

## University researchers

- [Lucely Cetina](https://scholariq.org/researchers/lucely-cetina/)

## University top topics

Showing 8 of 25.

- [Cervical Cancer and HPV Research](https://scholariq.org/topics/cervical-cancer-and-hpv-research/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Global Cancer Incidence and Screening](https://scholariq.org/topics/global-cancer-incidence-and-screening/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.